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Abstract
Background: Leptin, a cytokine-like protein, plays an important role in the regulation of body weight through inhibition of
food intake and stimulation of energy expenditure. Leptin circulates in blood and acts on the brain, which sends
downstream signals to regulate body weight. Leptin therapy has been successful in treating leptin deficient obese patients.
However, high levels of leptin have been observed in more common forms of obesity indicating a state of leptin resistance
which limits the application of leptin in the treatment of obesity. If the central effect of leptin could be by-passed and genes
which respond to leptin treatment could be regulated directly, new therapeutic targets for the treatment of obesity may be
possible. The purpose of this study was to identify genes and subsequent pathways correlated with leptin-mediated weight
loss.
Methodology/Principal Findings: We utilized microarray technology to compare hepatic gene expression changes after
two types of leptin administration: one involving a direct stimulatory effect when administered peripherally (subcutaneous:
SQ) and another that is indirect, involving a hypothalamic relay that suppresses food intake when leptin is administered
centrally (intracerebroventricular: ICV). We identified 214 genes that correlate with leptin mediated weight loss. Several
biological processes such as mitochondrial metabolic pathways, lipid metabolic and catabolic processes, lipid biosynthetic
processes, carboxylic acid metabolic processes, iron ion binding and glutathione S-transferases were downregulated after
leptin administration. In contrast, genes involved in the immune system inflammatory response and lysosomal activity were
found to be upregulated. Among the cellular compartments mitochondrion (32 genes), endoplasmic reticulum (22 genes)
and vacuole (8 genes) were significantly over represented.
Conclusions/Significance: In this study we have identified key molecular pathways and downstream genes which respond
to leptin treatment and are involved in leptin-mediated weight loss. Many of these genes have previously been shown to be
associated with obesity; however, we have also identified a number of other novel target genes. Further investigation will
be required to assess the possible use of these genes and their associated protein products as therapeutic targets for the
treatment of obesity.
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Introduction
Leptin, a cytokine-like protein containing 167 amino acids that
is predominantly expressed in adipocytes, was discovered in 1994
by positional cloning of the obese (ob) gene [1]. Leptin plays a very
important role in regulation of body weight and fat deposition
through the inhibition of food intake and stimulation of energy
expenditure [2]. Leptin-deficient (ob/ob) mice and leptin receptor-
deficient (db/db) mice are severely obese, infertile and insulin
resistant, have increased food intake, reduced body temperature
and decreased energy expenditure, immune function and bone
formation [3–5].
The liver has an integral role in lipid metabolism and also has
significant energetic demands; therefore, studies have suggested
that leptin’s effect on metabolism may be mediated by the liver.
Leptin-deficient mice have significant abnormalities in macronu-
trient metabolism, which can be corrected by leptin administra-
tion. A recent study has shown that acute leptin infusion rapidly
reverses hepatic steatosis and plasma dyslipidemia induced by a
high sucrose diet in rats [6], and the preservation of hepatic leptin
action after a high sucrose diet is associated with the maintenance
of low adiposity and plasma leptin concentrations.
Leptin therapy has been used to treat selected cases of both
congenital and acquired leptin deficiencies in humans. Leptin
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the adipose tissue. However, high levels of leptin have been
observed in obese humans and rodents, suggesting the develop-
ment of leptin resistance in these cases [7–10]. An important
component in leptin resistance appears to be the development of
defective leptin uptake into the brain, downregulation of leptin
receptors and decreased leptin sensitivity. The molecular mech-
anism by which leptin reduces body weight has been partially
elucidated. There is a need to have a precise understanding of the
metabolic pathways affected by leptin deficiency or leptin
resistance. Therefore, understanding the mechanisms by which
leptin and its targets influence energy balance could lead to new
therapeutic targets for obesity.
The purpose of this study was to identify the genes which
respond to leptin treatment and subsequent pathways correlated
with leptin-mediated weight loss. We utilized microarray technol-
ogy to compare two types of leptin administration: one involving a
direct stimulatory effect when administered peripherally (subcuta-
neous: SQ) and another that is indirect, involving a hypothalamic
relay that suppresses food intake when leptin is administered
centrally (intracerebroventricular: ICV). We report here the
impact of central and peripheral administration of leptin on food
intake, body weight and body fat composition in ob/ob mice. We
also report hepatic gene expression changes caused by central
versus peripheral leptin administration.
Materials and Methods
Animals and design
Leptin deficient (ob/ob) female mice (11 wk old) on the C57BL6
background were obtained from Jackson Laboratory (Bar Harbor,
ME). These mice were housed 2 per cage in shoebox cages with
food and water available ad libitum. Their health, body weight and
food intake were monitored and recorded weekly for 4 wk as they
adapted to the pellet diet (LabDiet 5010, PMI Nutrition
International). At 15 wk of age, the mice were divided into four
treatment groups such that the mean body weight between
treatments was not statistically different. Two groups of ten mice
each were subjected to the subcutaneous (SQ) treatment (vehicle
and leptin) and two groups of ten mice each were subjected to the
intracerebroventricular (ICV) treatment (vehicle and leptin).
Surprisingly, we observed negligible weight loss (ranging from
25.42% to 1.49%) in four animals of leptin-ICV treatment group,
in which the cannula may not have been in place or treatment did
not work. Therefore, these animals were removed from the analyses
while evaluating effects of leptin administration on body weight,
food intake and insulin levels. However, we thought that it would be
interesting to determine if the gene expression profile of these
animals were different from the animals showing weight loss.
Therefore, for microarray analyses, we sub divided the LEP-ICV
group into two groups: (a) LEP_ICV group: treatment worked
(weight lossrange:25%–38%)and(b)LEP_ICV*:treatmentdidnot
work (weight loss 25.42% to 1.49%). This resulted in total five
groups: VEH-SQ, LEP-SQ, VEH-ICV, LEP-ICV, and LEP-ICV*.
To minimize the cost of the experiment, we randomly selected mice
(n=4) from these five groups for microarray profiling.
Leptin Administration
Mice assigned to ICV treatments were surgically prepared with
unilateral cannulas directed towards the right lateral cerebral
ventricle as previously described [11]. Osmotic mini-pumps were
surgically placed SQ to provide continuous infusion of control
and test solutions for 12 days. For ICV treatments, polyethylene
tubing filled with 6ml artificial cerebrospinal fluid (aCSF) was
connected from the mini-pump to the ICV cannula. All mice
were allowed to recover for 2 days after surgery; during this time
6ml of saline or 6ml of aCSF were infused prior to the treatment
infusion. Leptin was continuously delivered subcutaneously (SQ;
Control: 6 ml/d saline; Leptin group: 10.0 mg/d leptin) or into
the lateral cerebral ventricle (ICV) (Control: 6 ml/d aCSF; Leptin
group: 1.5 mg/d leptin) via osmotic pumps for 12 days. Body
weight and food intakes were measured daily. Water was
available ad libitum. The mice were sedated with CO2, sacrificed
by guillotine prior to the collection of blood and tissues. Serum
samples were stored at 280uC until assayed. Insulin, was
determined using the Lumine6100
TM instrumentation and a
multiplex assay kit (Mouse Endocrine Immunoassay Panel
catalog # MENDO-75K, protocol - http://www.lincoresearch.
com/protocols/mendo-75k.html) manufactured by LINCO Re-
search, Inc (St. Charles, MO). Brains of mice assigned to ICV
treatments were sectioned to confirm proper cannula placement.
All surgical and experimental procedures in this study were
conducted in accordance with the NIH Guidelines and were
approved by the Animal Care and Use Committee for The
University of Georgia prior to initiating the studies under the
Animal Use Proposal # A2007-10224-0.
Microarray hybridization
Total RNA was isolated using TRI REAGENT (Sigma),
according to the manufacturer’s protocol. Purified RNA (200 ng)
was further used for cRNA amplification and labeling with biotin
using Target Amp cDNA synthesis kit (Epicenter catalog
no. TAB1R6924). Approximately 750ng of labeled cRNA was
hybridized to the MouseRef-8 v2.0 Expression BeadChips as per
manufacturer’s instructions. MouseRef-8 BeadChip targets 25,600
RefSeq transcripts and enables the interrogation of eight samples
in parallel. After hybridization, arrays were washed, stained with
Cy3-conjugated streptavidin, and scanned. Image data were
analyzed with BeadStudio V2.0. Raw intensity data from
BeadStudio were exported for further statistical analyses. The
microarray data are MIAME compliant and have been deposited
in NCBI Gene Expression Omnibus and are accessible through
GEO Series accession number GSE20878.
Differential gene expression analysis
Microarray data were normalized using the lumi package in R,
using the variance stabilizing transformation (VST) of the package
and robust spline normalization (RSN). Differential expression
analyses were conducted using the LIMMA (Linear Models for
Microarray Analysis) package from the Bioconductor project [12].
LIMMA uses an empirical Bayes approach that uses the variability
in all genes for testing for signficiant differences, with this
approach resulting in more stable inferences for a relatively small
number of arrays [12,13]. We used LIMMA to test for a linear
association between gene expression levels and amount of weight
loss (grams), using the amount of weight loss in a linear model and
testing for the significance of the regression coefficient for weight
loss. We used the false discovery rate (FDR) adjust for multiple
testing [14]. B-statistics (the log of the odds of a gene showing
either any association with weight loss) were calculated for each
gene. Duplicate genes, when present, were removed and their
expression levels averaged across the duplicates. We used a
combination of ‘‘B statistic’’ and absolute value of slope (logFC) for
selecting the differentially expressed genes. B statistic is the log
odds of a gene showing either positive or negative correlation with
weight loss (also known as a lod score) and logFC determines the
magnitude of change in expression with weight loss. We used a
cut-off of B.0 and logFC.0.02 (which corresponds to ,2-fold or
Leptin Signaling and Obesity
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weight loss point in graph). A total of 221 probes representing 214
unique genes were found significantly correlated with weight loss.
Cluster analysis
Cluster analysis was performed for grouping differentially
expressed genes exhibiting similar expression patterns using the
HPCluster program [15]. HPCluster is a two-stage algorithm: the
first stage is based on BIRCH (Balanced Iterative Reducing and
Clustering using Hierarchies), while the second stage is a
conventional k-Means. With BIRCH, a tree of cluster features
defining the partitioning of high dimensional space is generated,
followed by a conventional k-Means clustering of each cluster
feature obtained with BIRCH. Two hundred and fourteen genes
could be grouped into four clusters based on the expression data.
Gene ontology analysis
Associations of the 214 differentially expressed genes with
biological processes, molecular functions and cellular compartments
were annotated using the GOTree Machine [16]. The GOTree
Machine uses the hypergeometric test to evaluate the significance of
enrichment for each category by determining if the observed
number of gene counts exceeded the expected counts. The ‘‘FDR’’
method was used for adjusting the p-values for multiple testing. The
results were visualized as a directed acyclic graph (tree) in order to
show the relationship among the enriched GO categories.
Results
The present study was designed to identify hepatic genes and
pathways correlated with leptin mediated weight loss. Leptin
deficient ob/ob mice were continuously administered with leptin
via ICV (1.5 mg/d) or SQ (10 mg/d) over the 12-day treatment
period. Liver RNA was extracted and cDNA microarray
technology was used to explore the change in global gene
expression profiles after two types of leptin administration. The
four animals with negligible weight loss (ranging from 25.42% to
1.49%) after leptin-ICV treatment animals were removed from the
analyses while evaluating effects of leptin administration on body
weight, food intake and insulin levels. However we profiled these
animals for gene expression, and the data were included for
Identification of genes correlated with weight loss.
Effects of central and peripheral leptin administration on
body weight and food intake
Both central and peripheral leptin administrations caused a
significant reduction in food intake (FI) in leptin treated ob/ob mice
as compared to vehicle treated ob/ob mice (SQ: 3.6660.49 g
(leptin) vs 5.8060.79 g (vehile); ICV: 2.4560.65 g (leptin) vs
5.5760.65 g (vehile); Figure 1A). Similarly, there was a significant
reduction in body weight (BW) in both ICV & SQ leptin groups as
compared to their respective controls. Interestingly, percent weight
loss in the ICV leptin-treated group was significantly greater than
the weight loss in SQ leptin-treated group (SQ: 14.8961.15 g
(leptin) vs 24.5060.76 (vehile); ICV: 30.5162.87 g (leptin) vs
24.2360.78 g (vehile); Figure 1B). Values are mean 6 SEM.
Leptin administration decreases serum insulin levels
The 12 days of leptin infusion in ob/ob mice, resulted in a
s i g n i f i c a n td e c r e a s ei ns e r u mi n s u l i nl e v e l si nb o t hc e n t r a la n d
peripheral leptin treatment groups, as compared to their respective
controls (SQ: 91.7968.91 (leptin) vs 787.7670.74 pM (vehile); ICV:
29.2566.44 (leptin) vs 815.2698.15 pM (vehile), Figure 1C). There
was alsoa significant difference between the leptin-treated groups; the
decrease in the insulin levels being greater in the ICV group as
compared to the SQ group (Figure 1C). Values are mean 6 SEM.
Identification of genes correlated with leptin-mediated
weight loss
We adopted microarray technology to compare the global gene
expression profiles after the central (ICV) and peripheral (SQ)
leptin treatments in ob/ob mice. C57BL6 mice were used for the
baseline gene expression. Two hundred and twenty-one probes
representing 214 unique genes were found to be significantly
correlated with leptin mediated weight loss. We have listed the top
15 upregulated genes (with a two-fold or greater change in
expression for each treatment) in Table 1 and 37 downregulated
Figure 1. Effect of central (intracerebroventricular:ICV) or peripheral (subcutaneous:SQ) leptin treatment on food intake, weight
loss, and serum insulin levels in ob/ob mice. Leptin deficient, ob/ob mice were continuously administered with leptin over 12-days using central
or peripheral route of administration. Both types of leptin infusion significantly decrease food intake, weight, and serum insulin levels, as compared to
their respective controls. The weight loss caused by central treatment is significantly greater than the peripheral treatment. Also, the decrease in the
insulin level was more in the central group as compared to the peripheral group. VEH_SQ: vehicle subcutaneous treatment, LEP_SQ: leptin
subcutaneous treatment, VEH_ICV: vehicle intracerebroventricular treatment, LEP_ICV: leptin intracerebroventricular treatment. Values are mean 6
SEM; n=9 Veh_SQ, n=10 Lep_SQ, n=9 Veh_ICV and n=4 Lep_ICV; *P,0.05 leptin vs respective vehicle, { p,0.05 Lep_ICV vs Lep_SQ.
doi:10.1371/journal.pone.0012147.g001
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vs weigh loss graphs) of the top six upregulated and top six
downregulated genes mentioned above are shown in Figure 2. The
phenotype data and weight loss of four ICV leptin treated animals
(represented by red crossed circle) were very similar to the vehicle
treated animals. Sectioning of the brain could not confirm
placement of the cannula in two of these animals. As seen in the
heatmap and correlation plots, the expression of these animals is
very similar to the vehicle treated animals. Correlation plots of all
214 differentially expressed genes are available in supplementary
material (File S1: Top-214 Correlation plots.pdf).
Cluster analysis of correlated genes
Next, we performed cluster analyses on the 214 genes
significantly correlated with leptin mediated weight loss and found
4 clusters, each of which defined a unique pattern of expression
(Figure 3). The four animals in which the cannula may not have
been in place or treatment did not work are represented on the
heatmap as LEP-ICV*. The expression pattern of these animals is
similar to the vehicle groups. Seventy genes represented by cluster-
1 are overexpressed in ob/ob mice as compared to B6 mice. After
leptin replacement, the expression of these genes is normalized
towards B6 mice. Similarly, 46 genes in cluster-2 are under-
expressed in ob/ob as compared to B6 and leptin treatment could
correct the expression back to normal. 56 genes of cluster-3 and 42
genes of cluster-4 have similar expression in B6 and ob/ob but these
genes are downregulated (Cluster-3) or upregulated (Cluster-4)
after leptin treatment. The complete spreadsheet with gene
symbols and cluster assignment is available as supplementary
material (File S2: 214_Gene_matrix.xls).
Biological processes of genes regulated by leptin
treatment
Using the GOTree Machine web application [16], the 214
differentially expressed genes were categorized as being associated
with specific biological processes, molecular functions and cellular
compartments. Statistically significant over represented biological
processes were determined using the hypergeometric test. Among
the cellular compartments, mitochondrion (32 genes), endoplasmic
reticulum (22 genes) and vacuole (8 genes) were significantly over
represented. To determine if there was a difference in enrichment
of upregulated versus downregulated genes, the two groups (126
downregulated and 88 upregulated genes) were also mapped
separately to GO categories. The results were visualized as a gene
ontology tree in order to show the relationship among the enriched
GO categories (Figure 4). Several biological processes such as
cellular metabolic processes (101 genes), catabolic processes (36
genes), biosynthetic processes (28 genes), oxidation reduction (27
genes), response to chemical stimulus (35 genes), and inflammatory
response (10 genes) were found to be significantly over
represented. Among the molecular functions, oxidoreductase
activity (26 genes), cofactor binding (14 genes), catalytic activity
(89 genes), electron carrier activity (10 genes) and iron ion binding
(12 genes) were significantly over represented. The complete gene
ontology analyses results are available as supplementary material
(File S3: Gene Ontology.pdf).
Downregulated biological pathways after leptin
administration in ob/ob mice
Mitochondrial metabolic pathways. T h eg e n eo n t o l o g y
analyses revealed that most significantly enriched cellular
compartments among downregulated genes are mitochondrion
and endoplasmic reticulum. Thirty-two genes could be mapped
to mitochondrion, 26 genes were downregulated and 6 genes
were upregulated after leptin treatment (Table 3). The most
affected mitochondrial pathways are, ketone metabolic process,
organic acid metabolic process, oxidation reduction, amino acid
metabolic process, and nitrogen compound metabolic process.
Among the molecular functions, electron carrier activity,
catalytic activity, and coenzyme binding were most affected
Table 1. Top 15 upregulated genes involved in leptin mediated weight loss.
Symbol FC_SQ
a FC_ICV
b FC_ob/B6
c adj.P.Val
d Definition
Igfbp2 6.54 16.10 0.06 2.10E-08 insulin-like growth factor binding protein 2
Acot1 3.12 5.60 0.65 0.000739 acyl-CoA thioesterase 1
Lyz 2.33 4.93 0.41 0.000107 Lysozyme
Mat2a 2.55 4.10 0.37 0.000703 methionine adenosyltransferase II, alpha
Lpl 2.32 4.03 0.86 0.000211 lipoprotein lipase (Lpl)
Pla2g12a 2.04 4.57 0.66 0.000125 phospholipase A2, group XIIA
Wbp5 3.01 3.44 0.35 0.000535 WW domain binding protein 5
C1qb 2.32 3.22 0.28 0.000584 complement component 1, q subcomponent, beta polypeptide
H2-Ab1 2.52 2.88 0.50 0.001534 histocompatibility 2, class II antigen A, beta 1
Hadhb 2.04 3.17 0.99 0.000344 hydroxyacyl-Coenzyme A dehydrogenase
Egfr 2.58 2.48 0.16 0.001144 epidermal growth factor receptor
Slc25a33 2.60 2.43 0.38 0.000271 solute carrier family 25, member 33
Slc40a1 2.24 2.77 0.68 0.001166 solute carrier family 40 (iron-regulated transporter), member 1
LOC100046120 2.30 2.65 0.33 0.001791 s musculus similar to clusterin
Rps11 2.12 2.52 0.38 0.001243 ribosomal protein S11
aFC_SQ: fold change in gene expression after peripheral (subcutaneous) leptin administration as compared to vehicle subcutaneous treatment.
bFC_ICV: fold change in gene expression after central (intracerebroventricular) leptin administration as compared to vehicle intracerebroventricular treatment.
cFC_ob/B6: fold change in gene expression in vehicle treated ob/ob mice as compared to the expression in B6 mice.
dadj.P.Val: adj. p-value of regression analysis performed to test for a linear association between gene expression levels and amount of weight loss.
doi:10.1371/journal.pone.0012147.t001
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related to cellular metabolism is a characteristic of ob/ob mice,
while leptin replacement normalizes this expression back
t o w a r d sB 6 .T h el i v e r so fob/ob mice are overloaded with
large amounts of free fatty acids either through increased fatty
acid biosynthesis or through decreased fatty acid oxidation.
Leptin administration promotes a hypometabolic state and
downregulates cellular metabolic activity. Surprisingly, this
condition is very similar to hibernation [17]. The key to the
survival under hibernation lays in an inherent ability to
downregulate cellular metabolic rate to new hypometabolic
steady states. There was a downregulation of most genes
involved in amino acid metabolism, lipid, fatty acid and steroid
metabolism and oxidation/reduction after leptin treatment in
ob/ob mice. Mitochondrial metabolic pathways are major
regulators of leptin-mediated weight loss.
Lipid metabolic process. We found 26 genes differentially
expressed under lipid metabolic processes, out of which 19 genes
Table 2. Top 37 downregulated genes involved in leptin mediated weight loss.
Symbol FC_SQ
a FC_ICV
b FC_ob/B6
c adj.P.Val
d Definition
Scd1 0.05 0.01 4.60 3.33E-07 stearoyl-Coenzyme A desaturase 1
Gsta1 0.09 0.11 41.28 0.000125 glutathione S-transferase, alpha 1
Hamp2 0.32 0.03 2.16 8.76E-07 hepcidin antimicrobial peptide 2
Cyp17a1 0.24 0.17 2.59 6.85E-06 cytochrome P450, family 17, subfamily a, polypeptide 1
Ahcy 0.25 0.18 4.50 7.94E-05 S-adenosylhomocysteine hydrolase
Raet1b 0.41 0.12 7.26 8.76E-07 retinoic acid early transcript beta
Sardh 0.27 0.17 3.86 0.001766 sarcosine dehydrogenase
Gsta2 0.23 0.22 8.24 0.000131 glutathione S-transferase, alpha 2
Rdh16 0.29 0.20 5.93 5.65E-06 retinol dehydrogenase 16
Aass 0.29 0.22 4.63 0.000942 aminoadipate-semialdehyde synthase
Pla2g4f 0.23 0.28 4.14 0.000178 phospholipase A2, group IVF
Lrtm1 0.32 0.20 2.05 6.44E-05 leucine-rich repeats and transmembrane domains 1
Gstt3 0.41 0.12 2.67 2.13E-07 glutathione S-transferase, theta 3
Thrsp 0.35 0.21 0.90 0.000931 thyroid hormone responsive SPOT14 homolog
Bhmt 0.35 0.23 5.59 0.000696 betaine-homocysteine methyltransferase
Selenbp2 0.32 0.30 1.76 0.000285 selenium binding protein 2
Rcan2 0.30 0.33 3.01 8.09E-05 regulator of calcineurin 2
Mmd2 0.29 0.34 2.79 0.000309 monocyte to macrophage differentiation-associated 2
Gamt 0.36 0.29 1.85 0.000344 guanidinoacetate methyltransferase
Dmgdh 0.31 0.34 3.82 0.000703 dimethylglycine dehydrogenase precursor
Olig1 0.41 0.25 6.69 2.86E-06 oligodendrocyte transcription factor 1
Tmie 0.48 0.18 4.48 0.000109 transmembrane inner ear
Snhg11 0.35 0.31 3.98 0.000314 small nucleolar RNA host gene 11
Kcnk5 0.45 0.22 1.99 0.000682 potassium channel, subfamily K, member 5
Aes 0.36 0.31 2.66 0.000315 amino-terminal enhancer of split
Nnmt 0.48 0.21 1.29 0.002523 nicotinamide N-methyltransferase
9130409I23Rik 0.35 0.35 3.35 0.001156 RIKEN cDNA 9130409I23 gene
Slc38a4 0.40 0.32 5.60 0.002091 solute carrier family 38, member 4
Slc25a1 0.44 0.30 1.81 2.96E-05 solute carrier family 25 (mitochondrial carrier, citrate transporter), member 1
Uroc1 0.48 0.28 2.84 6.63E-05 urocanase domain containing 1
Hsd17b10 0.42 0.36 3.47 0.000125 hydroxysteroid (17-beta) dehydrogenase 10
Pls3 0.46 0.33 4.45 0.002206 plastin 3
Fam158a 0.44 0.39 2.84 0.00198 family with sequence similarity 158, member A
C530044N13Rik 0.47 0.39 3.14 0.002232 RIKEN cDNA C530044N13 gene
Slc44a1 0.48 0.40 2.09 5.28E-05 solute carrier family 44, member 1
Oprs1 0.47 0.43 2.03 0.001192 opioid receptor, sigma 1
Mfsd2 0.45 0.48 2.59 0.001226 major facilitator superfamily domain containing 2
aFC_SQ: fold change in gene expression after peripheral (subcutaneous) leptin administration as compared to vehicle subcutaneous treatment.
bFC_ICV: fold change in gene expression after central (intracerebroventricular) leptin administration as compared to vehicle intracerebroventricular treatment.
cFC_ob/B6: fold change in gene expression in vehicle treated ob/ob mice as compared to the expression in B6 mice.
dadj.P.Val: adj. p-value of regression analysis performed to test for a linear association between gene expression levels and amount of weight loss.
doi:10.1371/journal.pone.0012147.t002
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to lipid biosynthetic process, out of which 10 genes were
downregulated. Leptin influences the rates of synthesis and
degradation of lipids through its autocrine and paracrine actions.
The molecular mechanism of leptin action in fatty acid
metabolism and lipid biosynthesis has not yet been fully
elucidated. We found that Scd1, Faah, Acot1, Rdh16 and Lss
are downregulated by leptin treatment. The microsomal enzyme,
stearoyl-CoA desaturase-1 (Scd1) catalyzes the biosynthesis of
monounsaturated fatty acids from saturated fatty acids. In our
study we found that leptin-deficient ob/ob mice have very high
levels (,5-fold) of Scd1 gene expression as compared to B6 control
mice and after leptin replacement in ob/ob mice, the Scd1 gene
expression is extremely downregulated (,20-fold in SQ and
,100-fold in ICV) as compared to their respective controls.
Therefore, Scd1 appears to be a major player in the leptin
mediated lipid biosynthesis and fatty acid metabolism. This finding
is consistent with other studies which have shown that ob/ob mice
with mutations in Scd1 gene are significantly less obese than ob/ob
controls and have markedly increased energy expenditure. A
significant proportion of metabolic effects of leptin are the result of
inhibition of this enzyme [18]. On the other hand the Scd1
2/2
mice in SV129 background are lean, resistant to diet-induced
obesity, have increased insulin sensitivity, and increased metabolic
rate [19].
Carboxylic acid metabolic process. Twenty-four down-
regulated genes including Gck, Faah, Otc, Arg1, Gls2, Ass1,
Prodh and Aass, could be mapped to carboxylic acid metabolic
pathways. Glucokinase (GcK) regulates rate-limiting reactions in
glycolysis. Expression of Gck is regulated in the liver in response to
fasting and feeding. We found that Gck is 2-fold and 5-fold
downregulated after leptin administration. Hepatocyte nuclear
factor 4 alpha (HNF4alpha) plays an important role in
transcriptional regulation of GcK gene [20] and many genes
expressed in the liver. We found that HNF-4 has a downward
trend after leptin administration, but could not reach to statistical
significance. HNF4alpha is also critical for urea homeostasis by
direct regulation of the Otc gene [21]. Otc is a key enzyme in the
urea cycle to detoxify ammonium produced from amino acid
catabolism. Here, we found that Otc was also significantly
downregulated after leptin replacement.
Iron ion binding. In this study, we found that 12 genes could
be annotated to the iron ion binding group. The 9 downregulated
genes were Cisd1, Haao, Cyp17a1, Dpyd, Hpd, Scd1, Cyp2c29,
Ndufs8, and Sfxn1 and 3 upregulated genes of this group were
Cyba, Hpx and, Slc40a1. There is a well established link between
obesity and iron metabolism. Ob/ob mice have higher iron
absorption as compared to lean mice [22]. There is evidence in
the literature that insulin resistance is associated with hepatic iron
overload. A recent study found a role of Hepacidin expression in
Figure 2. Regression plots of top six downregulated and top six upregulated genes. The regression analysis was performed using ‘‘LIMMA’’
to identify genes whose expression is significantly correlated with leptin mediated weight loss. Blue open circle is vehicle subcutaneous treatment;
Blue filled circle is leptin subcutaneous treatment; Red open circle is vehicle intracerebroventricular treatment; Red filled circle is leptin
intracerebroventricular treatment; Red crossed circle is leptin intracerebroventricular treatment but no weight loss.
doi:10.1371/journal.pone.0012147.g002
Figure 3. Heatmap of 214 differentially expressed genes showing gene expression levels across different samples. Each row
represents one gene and each column represents one sample. Red indicates higher expression and green indicates lower expression. The global gene
expression profiles were compared after the central and peripheral leptin treatments in ob/ob mice, while C57BL6 mice were used for the baseline
gene expression. Cluster analysis on the gene expression data was performed to group the genes with similar expression patterns across
experimental conditions. VEH-SQ: vehicle subcutaneous treatment, LEP-SQ: leptin subcutaneous treatment, VEH-ICV: vehicle intracerebroventricular
treatment, LEP-ICV: leptin intracerebroventricular treatment, LEP-ICV*: represents four animals in which the cannula may not have been in place or
treatment failed. While analyzing the phenotype data, we found that there was no weight loss in these four animals. Sectioning of the brain could not
confirm placement of the cannula in these animals. The expression of these animals is very similar to the vehicle treated animals.
doi:10.1371/journal.pone.0012147.g003
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insulin resistance [23]. Interestingly, in our study, we also found
that expression of hepcidin antimicrobial peptide 2 (Hamp2) was
3-fold and 28-fold downregulated after leptin treatment.
Glutathione S Transferases. Glutathione is a major
endogenous anti-oxidant for the cell. We found that three of the
glutathione S-transferases were significantly overexpressed in ob/ob
mice as compared to B6 (Gsta1: 41-fold, Gsta2: 8-fold, Gstt3: 3-
fold). Also, leptin replacement caused the downregulation of
Gsta1, Gsta2, Gsta3, Gstt1 and Gstt3 in ob/ob mice. Reactive
oxygen species (ROS) production by mitochondria plays a critical
role in many physiological processes and therefore over quenching
of ROS in ob/ob mice may result in pathological conditions. A
recent study has shown that mice lacking one of the key enzymes
involved in the elimination of physiological ROS, glutathione
peroxidase 1 (Gpx1), were protected from high-fat-diet-induced
insulin resistance [24].
Genes involved in adipocyte proliferation and
differentiation. It is well known that adipocyte proliferation
and differentiation plays a critical role in obesity. Leptin causes
alterations in the expression of many genes which inhibit adipocyte
differentiation. The expression of Igfbp2 gene, which negatively
regulates the biological activity of IGF1, was 66 (SQ) and 166
(ICV) upregulated after leptin replacement. Igfbp2 is almost 176
downregulated in ob/ob mice as compared to B6. Another
mitochondrial gene, Cisd1 was 2.46 upregulated in ob/ob mice
as compared to B6 and corrected back to normal by leptin. This
protein encodes for MitoNEET protein which exists in low levels
in preadipocytes, and its expression increases exponentially in
differentiated adipocytes. Leptin has a mitogenic potential in liver
cancer cells, which is mediated through the induction of Mat2a
and Mat2b genes [25]. In this study, we found that expression of
Mat2a was induced after both types of leptin treatment.
Upregulated biological processes after leptin
administration in ob/ob Mice
Lysosomal activity. We found that the cellular compart-
ments enriched by upregulated genes were lysosome (5 genes),
vacuole (6 genes), and vesicle (9 genes). Lysosomes contain
enzymes which destroy organelles that have been damaged.
Also, when adequate amount of food is not available for the cell,
the organelle degradation and lysosomal activity is increased. A
Figure 4. Gene Ontology tree representing the cellular compartments enriched by upregulated and downregulated set of genes.
Gene ontology analysis was performed using the GOTree Machine software which performs the hypergeometric test to evaluate the significance of
enrichment for each category by determining if the observed number of gene counts exceeded the expected counts. Among the cellular
compartments mitochondrion and endoplasmic reticulum are enriched by downregulated genes and vacuole, vesicle, lysosome are significantly
enriched by upregulated genes.
doi:10.1371/journal.pone.0012147.g004
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autophagy in regulating intracellular lipid stores [26]. Lysosomes
continuously use portions of lipid droplets and process them for
energy production during nutrient deprivation [26].
Immune system and inflammatory response. Leptin has
structural similarities with the family of long-chain helical
cytokines, including IL-6 and IL-12 and also has been found to
play a critical regulatory role within the immune system that
affects the course of inflammation [27]. Various studies have
shown that immune cells respond to pharmacological doses of
leptin. In this study we found that the immune system process and
inflammatory response were enriched in the upregulated group of
genes. The genes which were upregulated in this group are; C1qb,
Cd44, Ccl4, Nupr1, Cyba, Fcer1g, Rmcs2, Fcer1g, Rps19, Plscr1,
Ednrb, Cd44, Ung, Ctnnb1, Lmo2, and Hpx. A recent study has
shown the function of leptin within T-cell polarization [28].
Utilizing the model of oxazolone-induced colitis, authors found
that ob/ob mice were protected, whereas wild-type and leptin-
reconstituted ob/ob mice developed colitis. This protection of Th1-
as well as in Th2-dependent inflammation was associated with
decreased expression of T-bet and GATA-3, in naive ob/ob T cells
[28]. In this study, we also found that epidermal growth factor
receptor (EGFR) expression was upregulated almost 2.5 times after
leptin replacement in ob/ob mice. It is known that EGFR mediates
both chemotaxis and proliferation in monocytes and macrophages
and treatment with EGFR inhibitor decreases the protein
expression of TNF-alpha and IL-6, and reduces subclinical
inflammation in HFD-fed mice [29].
Table 3. 32 mitochondrial genes involved in leptin signaling.
Symbol FC_SQ
a FC_ICV
b FC_ob/B6
c adj.P.Val
d Definition
Sardh 0.27 0.17 3.86 0.001766 sarcosine dehydrogenase
Aass 0.29 0.22 4.63 0.000942 aminoadipate-semialdehyde synthase
Gck 0.58 0.21 2.96 0.000114 Glucokinase
Abat 0.53 0.25 2.30 7.01E-05 4-aminobutyrate aminotransferase
Dmgdh 0.31 0.34 3.82 0.000703 dimethylglycine dehydrogenase precursor
Slc25a1 0.44 0.30 1.81 2.96E-05 solute carrier family 25 (mitochondrial carrier, citrate transporter), member 1
Hsd17b10 0.42 0.36 3.47 0.000125 hydroxysteroid (17-beta) dehydrogenase 10
Otc 0.82 0.32 1.71 0.002029 ornithine transcarbamylase
Cisd1 0.53 0.38 2.35 0.001166 CDGSH iron sulfur domain 1
Kynu 0.62 0.46 1.98 3.95E-05 kynureninase (L-kynurenine hydrolase)
Gcdh 0.57 0.52 1.67 0.000211 glutaryl-Coenzyme A dehydrogenase
Nipsnap1 0.69 0.48 1.61 1.01E-06 4-nitrophenylphosphatase domain and non-neuronal SNAP25-like protein homolog 1 (C.
elegans)
Ndufs8 0.62 0.51 1.47 0.001217 NADH dehydrogenase (ubiquinone) Fe-S protein 8
Sfxn1 0.76 0.55 1.77 1.61E-05 sideroflexin 1
Dbi 0.60 0.61 2.05 0.000292 diazepam binding inhibitor
Cyp17a1 0.24 0.17 2.59 6.85E-06 cytochrome P450, family 17, subfamily a, polypeptide 1
Haao 0.57 0.20 1.26 0.000502 3-hydroxyanthranilate 3,4-dioxygenase
Prodh 0.61 0.21 1.35 2.57E-05 proline dehydrogenase
Gls2 0.73 0.25 0.84 1.45E-03 glutaminase 2 (liver, mitochondrial)
Ass1 0.80 0.34 0.94 0.001664 argininosuccinate synthetase 1
Mmab 0.75 0.47 0.95 2.96E-05 methylmalonic aciduria (cobalamin deficiency) type B homolog (human)
Macrod1 0.95 0.50 0.64 0.001609 MACRO domain containing 1
Cyb5r3 0.60 0.56 1.04 0.000137 cytochrome b5 reductase 3
Hsd3b2 0.83 0.49 1.13 0.000502 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2
Ndufa3 0.74 0.60 1.08 0.000687 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 3
Uqcrc1 0.58 0.64 1.24 0.000902 ubiquinol-cytochrome c reductase core protein 1
Hadhb 2.04 3.17 0.99 0.000344 hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme A thiolase/enoyl-
Coenzyme A hydratase (trifunctional protein), beta subunit
Ung 1.27 2.95 0.76 0.00021 uracil DNA glycosylase
Mrps6 1.20 1.91 0.92 0.002234 mitochondrial ribosomal protein S6
Slc25a33 2.60 2.43 0.38 0.000271 solute carrier family 25, member 33
Hsp90ab1 1.69 2.32 0.47 0.001625 heat shock protein 90kDa alpha (cytosolic), class B member 1
Cyba 1.20 2.00 0.68 7.33E-05 cytochrome b-245, alpha polypeptide
aFC_SQ: fold change in gene expression after peripheral (subcutaneous) leptin administration as compared to vehicle subcutaneous treatment.
bFC_ICV: fold change in gene expression after central (intracerebroventricular) leptin administration as compared to vehicle intracerebroventricular treatment.
cFC_ob/B6: fold change in gene expression in vehicle treated ob/ob mice as compared to the expression in B6 mice.
dadj.P.Val: adj. p-value of regression analysis performed to test for a linear association between gene expression levels and amount of weight loss.
doi:10.1371/journal.pone.0012147.t003
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after leptin treatment in ob/ob mice
Cluster analysis revealed that 214 differentially expressed genes
could be sub-divided into two major groups: (A) 116 genes of
Cluster-1 and Cluster-2, which have different expression in ob/ob
when compared to B6, and leptin treatment normalizes the
expression in ob/ob towards B6; (B) 98 genes of Cluster-3 and
Cluster-4, which have similar expression in ob/ob and B6 but are
downregulated or upregulated after leptin treatment. These two
groups of genes were separately analyzed and were mapped to
cellular compartments and biological functions (Table S1). The
enriched cellular compartments in both groups were mitochon-
drion (group A: 19 genes; group B: 14 genes), cytosol (group A: 10
genes; group B: 10 genes) and endoplasmic reticulum (group A: 11
genes; group B: 11 genes). However, the plasma membrane (6
genes) and vacuole/lysosome (5 genes) were only enriched in
group B. We have listed the comparison of enriched biological
processes of each group in Table S1. Both groups are enriched in
many metabolic processes whereas major catabolic processes are
mainly enriched in group A. We also found that steroid metabolic
process is only enriched in Group B and the genes involved in this
process are Gpsn2, Cyb5r3, Lss, Cyp17a1, Pcsk9, Mvd, Hsd3b2.
Network Analysis. Differentially expressed genes were
further analyzed using Ingenuity Pathway Analysis software
(IPA; Ingenuity Systems, Mountain View, CA; www.ingenuity.
com) to construct and visualize molecular interaction networks.
Three high scoring networks could be identified. Network-1
(Figure 5) is enriched in lipid metabolism and cell-cell signaling.
EGFR (which is upregulated after leptin treatment) is one of the
central hub genes of this network. Also a lot of genes involved in
this network are connected through important kinases. Expression
of these kinases does not change after leptin replacement, but these
might be mediators for the signal transduction between the genes
which respond to leptin treatment. The transcriptional regulators
in the network are Ets2, Xbp1, Sap30, Nupr1, Hmga1, Zfp36,
Maged1 and Cttnb1. Network-2 and 3 are available in
supplementary material (File S4: Networks.pdf). Network-2 is
enriched in lipid metabolism and cell cycle and involves many
cytokines. Network-3 is enriched in cell morphology and most of
the genes in this network are connected through Hnf4a, Ifng and
Htt.
Discussion
Despite the fact that leptin has shown exciting results in the
mouse models, the success rate of leptin for the reduction of body
weight in humans is very low. This is due mainly to the fact that a
very small fraction of the obese human population is leptin
deficient, and the most common forms of obesity are associated
Figure 5. Top scoring network obtained from network analysis of differentially expressed genes. Ingenuity Pathway Analysis software
was used to construct and visualize molecular interaction networks.
doi:10.1371/journal.pone.0012147.g005
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leptin resistant and fail to respond effectively to exogenous leptin
[8]. Several defects may contribute to the leptin resistant state,
including defective leptin transport across the blood-brain barrier,
reduced leptin receptor expression, defects in leptin signal
transduction, or the induction of feedback inhibitors [10] [7].
However, if leptin resistance could be by-passed and genes/
pathways which respond to leptin treatment could be regulated
directly, new therapeutic strategies for the treatment of obesity
may be possible. In this study, we determined the global hepatic
gene expression profiles after peripheral and central leptin
treatment. We found that the effect of central treatment on
weight loss was significantly better than peripheral treatment;
which confirms that leptin action on weight loss is primarily
controlled by a central pathway via hypothalamic relay. We found
214 genes significantly correlated with leptin-mediated weight loss.
Obesity results from the imbalance of energy intake and energy
utilization. When energy intake exceeds energy expenditure,
excess energy is stored as triglycerides in lipid droplets. Conversely
during nutrient deprivation, stored triglycerides are hydrolyzed
into fatty acids and converted back to energy. Therefore,
metabolic pathways are key regulators of energy balance. In this
study, we found that genes which belong to metabolic, catabolic
and biosynthetic pathways in mitochondria are highly expressed in
ob/ob mice when compared with the B6 baseline expression.
However, leptin replacement results in the downregulation of
these pathways back to normal. The Stearoyl-CoA Desaturase 1
(Scd1), which is a lipogenic enzyme involved in fatty acid synthesis
and oxidation, is overexpressed in the livers of ob/ob mice as
compared to B6 and is downregulated after leptin replacement.
This is consistent with the results of previous studies which have
shown that Scd1 deficient mice are protected against obesity and
insulin resistance [18,19]. Also in humans, genetic variations in the
Scd1 gene were found to be associated with body fat deposition
and insulin sensitivity [30]. Some recent studies have used
pharmacological inhibition of Scd1 for treatment of obesity and
insulin resistance [31,32]. Glucokinase (GcK) phosphorylates
glucose to produce glucose-6-phosphate and therefore regulates
glucose metabolism. We found that expression of this gene is
negatively correlated with leptin-mediated weight loss in ob/ob
mice. Long-term overexpression of Gck increases hepatic
lipogenesis and circulating lipids, which leads to insulin resistance
[33].
Weight loss also has been linked to GH-IGF1 axis in the
literature, which has a critical role in the proliferation and
differentiation of adipocytes [34]. IGF-binding proteins (IGFBPs)
modulate bioavailability of IGF. In this study we found that
Igfbp2 was highly underexpressed in livers of ob/ob mice but was
normalized after leptin replacement. Recent studies have shown
that overexpression of Igfbp2 protects against the development
of obesity and improves insulin sensitivity [35]. Treatment with
recombinant Igfbp2 impairs 3T3-L1 differentiation and hence
adipogenesis [35]. Elevated insulin and body fat have been
shown to be associated with decreased Igfbp1 and Igfbp2 levels
cross-sectionally [36]. A recent study observed markedly lower
expression of Igfbp2 in liver from morbidly obese women [37].
Such studies provide an impetus for investigating the effects of
Igfbp2 for treatment of obesity. However, studies have also
shown that Igfbp2 is overexpressed in a wide spectrum of cancers
and IGF-independent effects of Igfbp2 are emerging [38]. Igfbp2
expression was significantly higher in breast cancer tissue
compared with benign breast tissue and Igfbp2 inhibition
attenuated the associated aggressive phenotype of breast cancer
cells both in vitro and in vivo [39]. Overexpression of Igfbp2 has
also been correlated with glioblastoma [40,41] and lymph node
metastasis in patients with invasive breast carcinomas [42].
These findings suggest that further studies are required to
evaluate IGF-dependent and -independent functions of Igfbp2
before choosing Igfbp2 as a therapeutic target for treatment of
obesity.
We found that Cisd1, the mitochondrial gene which encodes for
the MitoNEET protein, is upregulated in livers of ob/ob mice as
compared to B6 and could be normalized by leptin. MitoNEET is
an iron-containing outer mitochondrial membrane protein that
regulates oxidative capacity and is involved in the control of
maximal mitochondrial respiratory rates [43]. This protein exists
in low levels in preadipocytes, and its expression increases
exponentially in differentiated adipocytes. Also, MitoNEET has
been identified as a target for the thiazolidinedione class of
diabetes drugs that may contribute to lipid lowering and/or
antidiabetic actions [44].
Interestingly, the expression of five glutathione S-transferases
(Gsta1, Gsta2, Gsta3, Gstt1, and Gstt3) were significantly down-
regulated after leptin administration. In an earlier study it was
shown that Gsta3 expression is markedly induced during adipose
conversion,whichisvirtually undetectableinconfluent 3T3-L1cells
under basal conditions [45]. Inhibition of the 3T3-L1 adipogenic
program demonstrated that Gsta3 expression is associated specif-
ically with acquisition of the adipocytic phenotype.
One important finding of this study was the upregulation of
hepatic lysosomal pathways, including vesicles and vacuole,
after leptin treatment. This finding is consistent with a recent
study which has identified the previously unknown role of
autophagy in regulating intracellular lipid stores [26]. Starva-
tion causes the induction of autophagy, which delivers
intracellular proteins and organelles sequestered in double-
membrane vesicles (autophagosomes) to lysosomes for degrada-
tion and use as an energy source. It was found that inhibition of
autophagy in cultured hepatocytes and mouse liver increased
triglyceride storage in lipid droplets.
In conclusion, this study identified key molecular pathways
and downstream target genes involved in the leptin-mediated
weight loss. Many of these genes have previously been shown to
be associated with obesity; however, we also identified a number
of novel target genes. Further detailed studies will be required to
evaluate the possible use of these genes and the associated
protein products as therapeutic targets for the treatment of
obesity.
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